Information  X 
Enter a valid email address

Synairgen narrows H1 pretax loss to £1.2m

By BFN News | 07:36 AM | Monday 12 August, 2013

Synairgen narrowed its first-half pretax loss to £1.19 million, from a loss of £1.26 million. It booked nil revenue. Total administrative expenses was £1.20 million, from £1.28 million. Chairman Simon Shaw said: "Significant progress has been made in the first six months of 2013. The company has been preparing for the commencement of a follow-on clinical trial in asthma, which it intends to conduct in partnership with a pharmaceutical company. "This process has been progressing well with a number of parties and the company will update the market in due course. "In parallel, the company has also taken steps which will lead to the assessment of SNG001 in severe viral lung infections with US Government agencies. Although this is at an early stage it is an exciting endorsement of SNG001's potential in viral defence." Story provided by

a d v e r t i s e m e n t